CLS raises up to 37 MSEK through directed share issue
CLS is conducting a directed issue of units, initially raising approximately SEK 16 million. If all warrants are exercised in September 2025, the company could receive an additional SEK 21 million. The issue is directed at several investors, including existing shareholders such as Khattar Holdings and Niklas Estensson.
– We welcome strategic and long-term investors who share our vision. The directed share issue strengthens our financial position and enables us to accelerate the commercialisation of our neurosurgical product offerings, while maintaining focus on sustainable growth, says Dan Mogren, CEO of Clinical Laserthermia Systems (CLS).
Over the past year, the company has concentrated on its strategic collaboration in neurosurgery with ClearPoint Neuro and the commercialisation of the ClearPoint Prism Neuro Laser Therapy System in the U.S.
To finance these commercialisation efforts, the board has decided to carry out a directed issue of 5.5 million units, consisting of shares of series B and warrants of series TO 8B. The subscription price is set at 2.90 SEK per unit, corresponding to 2.90 SEK per new B share.
The subscription price represents a discount of approximately 17.8 per cent against the 10-day volume weighted average price up to and including February 26.
Capital injection in two phases
Through the directed issue, the company initially raises approximately SEK 16 million, with a potential additional SEK 21 million in September through the exercise of TO 8B warrants. The warrants are issued free of charge and entitle holders to subscribe for one additional B share per warrant during the period September 15–27, 2025, at an exercise price of 3.80 SEK per share.
The share issue will result in an initial dilution of approximately 21.4 per cent of the number of shares and votes in CLS. Full exercise of the TO 8B warrants would lead to an additional dilution of approximately 17.6 per cent.
Strengthened cash position and shareholder base
The directed issue broadens and strengthens the company’s shareholder base with reputable investors.
– With this support, we are well positioned to execute on our strategy and drive CLS further towards profitability, comments Dan Mogren, CEO of CLS.
The capital injection will be used to secure the company’s operational capacity, improve its product portfolio and conducting regulatory approval processes, and strengthen its supply chain and quality assurance.
CLS has not only focused on securing new capital, but also on cost reduction by prioritising the most profitable business segments and using an expanded partner model. As a result, operating expenses are expected to decrease by at least 30 per cent in 2025, while the gross margin is expected to increase to at least 60 per cent by 2026.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
